Biocryst Pharmaceuticals Inc (NASDAQ:BCRX) was top riser on Nasdaq on Thursday as the group unveiled positive results from a phase 2 clinical trial of its oral inhibitor for severe swelling condition hereditary angioedema (HAE).
The study is a 3-part dose ranging trial designed to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered once-daily (QD) BCX7353 for 28 days, as a preventative treatment to reduce the frequency of attacks.
This second interim analysis assessed data from all patients in the first two parts of the trial
"These data support our hypothesis regarding the initial findings seen from the first interim analysis," said chief executive Jon Stonehouse.
"We are delighted to see that a daily dose of 125 mg of BCX7353 results in a high level of efficacy with an improved tolerability profile compared to the 350 mg dose observed in the first interim analysis.
"We look forward to completing Part 3 of the trial to select appropriate doses for our pivotal program."
Shares raced up over 31% to $6.73 each.